DAPA-HF trial affirms similar benefit to diabetes drug regardless of type 2 diabetes status
PARIS -- Dapagliflozin (Farxiga) lowered the risk of cardiovascular death and decompensation, and improved symptoms in heart failure (HF) with reduced ejection fraction (HFrEF), the DAPA-HF trial found.